Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Calcitriol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 10/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 2/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 2/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | GC | P02774 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | RXRA | P19793 | 1/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calcitriol SCHEMBL3488822 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL2641696 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL2733051 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL15169024 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL24066838 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL14027727 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL23386523 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL13989116 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL17973736 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 | |
| Calcitriol SCHEMBL21055106 | 1.00 | VDR (1.00) | VDRMAPTADORA3SLC6A2AGTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1729 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034149-A1 | ENHANCED SALICYLIC ACID AND DRUG DELIVERY FOR AQUEOUS TOPICAL APPLICATIONS | Otiko, Christopher Ayo (US) | 2026-02-05 | — | — | US | claimed |
| US-12465567-B2 | Enhanced antibiotic and drug delivery for aqueous topical applications for human and veterinary uses | Otiko, Christopher Ayo (US) | 2025-11-11 | — | — | US | claimed |
| US-20250228874-A1 | CALCITRIOL OR CALCITRIOL ANALOGUES FOR TREATING PERIPERHAL NEUROPATHIC PAIN DISORDERS | EPTIVA THERAPEUTICS LTD. (GB) | 2025-07-17 | — | — | US | claimed |
| US-12343421-B2 | Vitamin D base layer | Solaana MD LLC (US) | 2025-07-01 | — | — | US | claimed |
| US-20240392280-A1 | PRODUCTS AND METHODS FOR ASSESSING AND INCREASING KLOTHO PROTEIN LEVELS | KLOTHO THERAPEUTICS, INC. | 2024-11-28 | — | — | US | claimed |
| US-20230225386-A1 | HYDROGEN-GENERATING COMPOSITION FOR DIETARY AND AGRICULTURAL APPLICATIONS | H2 UNIVERSE LLC | 2023-07-20 | — | — | US | claimed |
| CN-111141814-B | Kidney endocrine detection device based on protein map | 山东大学齐鲁医院(青岛) | 2023-01-24 | — | — | CN | claimed |
| US-11555007-B2 | Compositions and methods for the treatment of neurological diseases | CELLIX BIO PRIVATE LIMITED (IN) | 2023-01-17 | — | — | US | claimed |
| EP-4003273-A1 | ENHANCED ANTIBIOTIC AND DRUG DELIVERY FOR AQUEOUS TOPICAL APPLICATIONS FOR HUMAN AND VETERINARY USES | Otiko, Christopher, Ayo (US) | 2022-06-01 | — | — | EP | claimed |
| US-20220105052-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN | CELLIX BIO PRIVATE LIMITED (IN) | 2022-04-07 | — | — | US | claimed |
| WO-1993019759-A1 | VITAMIN D DERIVATIVE FEED COMPOSITIONS AND METHODS OF USE | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1993-10-14 | — | — | WO | claimed |
| EP-0544391-A1 | Compositions for topical treatment of psoriasis and atopic dermatitis | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1993-06-02 | — | — | EP | claimed |
| US-5183817-A | Synergistic stimulants to treat alopecia | BAZZANO GAIL S (US) | 1993-02-02 | — | — | US | claimed |
| EP-0512814-A1 | Cosmetic composition | UNILEVER PLC (GB) | 1992-11-11 | — | — | EP | claimed |
| EP-0301167-B1 | A COMBINATION OF CHOLECALCIFEROL DERIVATIVES FOR THE TREATMENT OF RENAL BONE DISEASE | Teva Pharmaceutical Industries Limited (IL) | 1992-08-19 | — | — | EP | claimed |
| WO-1990009179-A1 | TREATMENT OF TIBIAL DYSCHONDROPLASIA | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 1990-08-23 | — | — | WO | claimed |
| EP-0301167-A1 | A combination of cholecalciferol derivatives for the treatment of renal bone disease | Teva Pharmaceutical Industries Limited (IL) | 1989-02-01 | — | — | EP | claimed |
| US-4225596-A | Method for treating calcium imbalance and improving calcium absorption in mammals | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1980-09-30 | — | — | US | claimed |
| US-4110446-A | METHOD OF TREATING MILK FEVER IN DAIRY CATTLE WITH 1,25-DIHYDROXYCHOLECALCIFEROL | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1978-08-29 | — | — | US | claimed |
| US-4035493-A | Rodenticide | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1977-07-12 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11555007-B2 | Compositions and methods for the treatment of neurological diseases | SCNN1G, PMP22, TTR | VDR 2273/4885MAPT 64/4885ADORA3 2027/4885 |
| US-20260034149-A1 | ENHANCED SALICYLIC ACID AND DRUG DELIVERY FOR AQUEOUS TOPICAL APPLICATIONS | VDR, DSG1, CYP2R1 | VDR 1/4885MAPT 2084/4885ADORA3 765/4885 |
| US-20220105052-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN | OPRK1, F5, F12 | VDR 776/4885MAPT 2999/4885ADORA3 1019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.